{"id":407181,"date":"2021-01-04T06:03:26","date_gmt":"2021-01-04T11:03:26","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=407181"},"modified":"2021-01-04T06:03:26","modified_gmt":"2021-01-04T11:03:26","slug":"reminder-cytodyn-to-hold-webcast-on-january-6-to-provide-timelines-for-clinical-and-regulatory-developments-submission-of-4-hiv-blas-and-eua-requests-for-covid-in-different-countries","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-cytodyn-to-hold-webcast-on-january-6-to-provide-timelines-for-clinical-and-regulatory-developments-submission-of-4-hiv-blas-and-eua-requests-for-covid-in-different-countries\/","title":{"rendered":"REMINDER: CytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different Countries"},"content":{"rendered":"
\n

\n Correction to inclusion\/exclusion criteria for eIND authorization<\/em>\n <\/p>\n

VANCOUVER, Washington, Jan. 04, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY)<\/strong>, (\u201cCytoDyn\u201d or the \u201cCompany”), a late-stage biotechnology company developing Vyrologix\u2122 (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Mahboob Rahman, M.D., Ph.D., Chief Scientific Officer, will host an investment community webcast on Wednesday, January 6, 2021.<\/p>\n

Management will provide an update on recent clinical and regulatory developments regarding COVID-19 clinical trials, along with other strategic priorities:<\/p>\n

1) BLA\/MAA submissions to Health Canada, MHRA, EMA, and US FDA
2) HIV prevention trial\/monotherapy trial
3) Potential revenue from HIV and manufacturing forecast
4) HIV Cure – amfAR
5) EUA submission timelines to same four agencies for COVID-19, if CD12 Trial results are \u00a0supportive of an EUA
6) Long-hauler clinical trial and potential data readout timelines
7) NASH trial and potential interim analysis timeline
8) Cancer trial Breakthrough Therapy designation potential timelines
9) GvHD trial status
10) Stroke\/MS new trials in 2021
11) NASDAQ uplisting status<\/p>\n

Management will also provide approximately 30-45 minutes to address questions submitted online by analysts and investors.<\/p>\n

\n Date: <\/strong>\u00a0Wednesday, January 6, 2021
Time:<\/strong> \u00a01:00 pm PT \/ 4:00 pm ET
Dial-In:<\/strong> \u00a0None.
Questions: <\/strong>\u00a0<\/p>\n